Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in ...

(OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class ...

Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...

Summit Therapeutics Inc. SMMT partner Akeso Inc. on Sunday revealed overall survival data from the Phase 3 HARMONi-2 trial ...

Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its proprietary PD-L1/4-1BB bispecific ...

Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts We initiated ...

The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also ...

As of the data cutoff on August 20, 2026, the median follow-up was 36 months, and a total of 234 overall survival (OS) events had occurred. For this OS analysis, a prespecified O'Brien-Fleming ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...

Selective removal of soluble tumor necrosis factor receptors by apheresis as a novel immunotherapy approach for triple-negative breast cancer. Outcomes with A+nP according to PD-L1 and aDDR status.